Join Comagine Health for the second session of a six-part weekly series to help Utah providers develop or augment a medication for opioid use disorder (MOUD) program with special considerations for COVID-19.
This series is designed for clinicians and administrators who are looking to build or grow a MOUD program that immediately impacts patients' lives. Building a MOUD program doesn’t require advertising or adding new patients – you already have patients in your practice you can treat today!
Participants will be provided with direction in setting up or growing a MOUD program, including guidance on:
How to discuss MOUD with your staff
How to accurately identify which patients will benefit and resources for those who need extra assistance
Policy, procedure, visit templates and billing
Risk mitigation strategies
All sessions will be held virtually on Wednesdays from 12:30 p.m. to 1:30 p.m. MT and will run from Nov. 4 to Dec. 9, 2020. CE credits are available (1.0 per session hours in AMA PRA Category 1 Credit(s)™)
Session 1: Introduction
Participants will understand the ECHO model®, including logistics
Participants will understand steps required to launch or enhance MOUD program
Participants will understand opioid use disorder terminology
Session 2: Finding the Right Patients for Your Program
How to identify patients appropriate for MOUD for your primary care practice
What to do with the patients that are, and are not, ready for outpatient treatment
Session 3: Patient Throughput and Roles
Brief overview of medicines
Identify the people, processes and documentation involved
Identify the quality metrics associated with a MOUD program
Session 4: Risk Mitigation and Patient Communication
Identify common deviations to treatment protocol and corresponding policy response(s)
Identify policy-related communications strategies for use with patients
Session 5: MOUD Program Development
Understand patient costs – common process
Understand insurance issues
Considerations for COVID-19
Session 6: Roundtable Report
Everyone report on where they were, and where they are now – discuss the gap between the ideal state discussed in Session 1 and today
Subject Matter Experts
Dr. Paula Cook is currently the chief medical officer for a large nonprofit treatment program and primary care clinic targeting people with addiction. She has extensive experience in addiction medicine and developing controlled substance monitoring programs for rural communities. She was one of the primary developers of the University of Utah’s Bridge program. She is a mentor for the Opioid Response Network program and is the president-elect of the Utah Chapter of ASAM.
Dr. Darlene Petersen is a family and addiction medicine physician in Roy, Utah, and is the medical director of Rock Run Family Medicine. She has previous experience on the NQF Opioid Technical Expert Panel to give her expertise in decisions for quality measures in value-based payment and reporting modules under Medicare. She is also on the Davis Hospital Controlled Substance Committee and is a member of the AAFP Opioid Advisory Committee.
Dr. J.K. Costello is a physician and consultant on population health for addictions. He works at the intersection of medicine, behavioral health and community recovery, fostering recovery-oriented systems of care. He helped introduce medication-assisted treatment in jails all over Colorado, resulting in hundreds of additional people being treated for OUD. He has worked with the state Medicaid agency to assess addiction treatment capacity, helped overhaul behavioral health in jails and assisted a dozen clinics with addiction treatment program implementation.
Contact Senior Improvement Advisor Rebecca Wilson with questions at firstname.lastname@example.org or 801-892-6616.
Comagine Health is accredited by the New Mexico Medical Society to provide continuing medical education for physicians. Comagine Health designates this Recurring Scheduled Series for maximum of 1.0 per session attended AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.